How deadly is Prostate cancer?

["Aka pagina ist'ma"]

¿Próstata usux kunjam jiwayirisa?

Cáncer de próstata ukax uraqpachan chachanakan payïr cáncer usüwipawa, 2018 maranx 1.276 waranq machaq usutaw utji, ukax 7,1% taqi chachanakan cáncer usunakapatakiwa.

Cáncer de próstata ukan jiwañapax wali jach'awa, 2018 maranx uraqpachanx 37.005 jiwataw utji.

Ukampirus, tasa de mortalidad ukax sapa región uksanx mayj mayjawa, África Occidental uksanx quinto lugar ukhanw cáncer de próstata ukan jiwañapax utji, Nigeria markanx jilpachax markachirinakaniwa ukatx economía uksanx nayrar sartir markawa.

Nigeria markanxa, cáncer de próstata ukax taqi chaqan wali uñt'ata ukhamarak jiwañamp piykatiri cancer ukhamawa, niya 32,8 usumpita 16,3 jiwañampitakiw 100,000 chachanakat utji.

Akax América del Norte ukanx pä kutiw juk'amp jiwata.

Qhiphar uñjat usunaka, uñakipañatak juk'a yänaka, ukat juk'ak qillqatanaka ukat yatiyatanakax Nigeria markanx walja jiwirinakarakiw utji.

Estados Unidos markanxa, próstata usunxa, payïri causa de muerte por cáncer ukaw utji, sapa maraw niya 40 000 chachanakax jiwapxi.

Aka cáncer de próstata usux 1990 maratpach juk'at juk'at aynacht'aski, ukampirus wali jan walt'aykakiwa.

Taqpachatxa, cáncer de próstata ukax mä jiwañ usuwa, juk'ampis kawkir chiqanakantix qullayasiñanakas uñakipañanakas juk'akiw utji uka chiqanakanxa.

Ukampirus, nayrïr uñstayäwimp qullayasiñampix wali askiw sartayaspa, ukhamat jiwañ juk'aptayaraksna.

['Qillqatanaka']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

["Jan jark'añataki: qullasiñataki"]

['Aka sitio webjja, yatichäwinak churañatakikiw lurasi, janiw mä doctoran yatichäwinakapak churkiti.']

['Uka yatiyäwinakajja, janiw usunakata, jan ukajj usunakata qollañatak yanaptʼkiti, ukat khitinakatï qollañ munapki ukanakajj mä doctorampiw yatjjatapjjañapa.']

["Amuyam, red neuronal ukax jiskt'anakar jaysäwinak utjayi, ukax janiw chiqakiti kunawsatix jakhuwinak utjki ukjaxa. sañäni, qawqha jaqinakatix mä usump usuntat jikxatasipxi."]

["Aka sitio web ukax janiw kunapachas mä qullirimpis usutampis apnaqayasiñatakïkiti. BioMedLib, irnaqirinakapasa, jan ukax aka sitio web ukar yanapt'irinakasa, janiw kuna arsüwinaksa, qhanañchata jan ukax qhanachata, aka chiqan utjki uka yatiyäwinakxatx lurapkiti."]

['Arxatasiña: derechos de autor']

["Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (DMCA) ukax derechos de autor ukankirinakaruw arxati, Internet ukan uñstir yänakax derechos de autor de EE.UU. ukar janiw walt'aykiti. "]

["Jumatix amuykta aka web tuqin utjki uka yänakax derechos de autor ukanakamarux janiw walt'aykiti, jumati jan ukax wakichirimasa uka yänakax apaqatäñapa jan ukax jark'aqatäñapa mayispa."]

['Yatiyäwinakax qillqawtuqit apayatani (celular tuqi yatiyañatakix "Contacto" siski uka chiq uñxatt\'ama).']

["DMCAx siwa, yatiyawimax aka manqhaxan qhananchatañapawa: (1) aka manqhaxan utjki uka waraqat'ata, (2) manqhaxan utjki uka waraqat'ata, ukata uka waraqat'at jikxatañataki wakisiri qhananchawinaka; (3) jumata aruskipañataki, akhama sutinaka: direccionama, teléfono tuqina, correo electrónico tuqina; (4) jumata qhanstayaña, uka manqhaxan utjki uka waraqat'ata, jan uka copyright ukanini, jan ukax uka wakichata jan ukax uka kamachirjama jan walikitapa."]

["5) jumati aka yatiyawx chiqpachapun yatiyatama, ukhamarak uka derechos de autor ukanakxat arxatirjamax janiw chiqaparux arxatktati sasin sañatak mä arsüwi qillqantäta, ukarux k'ari juramentompiw phuqhatani."]

['Ukjamaraki (6) derechos de autor ukanin sutinakapamp qillqantat chimpupa jan ukax electrónica chimpupa.']

["Janitix taqi uka yatiyawinakax qillqatäkanixa, janiw jank'as jank'as jan walt'awix askichatäkaniti."]

["Uñt'ayasiña"]

["Kuna jiskt'äwimpis / amuyt'äwimpis emailtuqir apayanipxita."]

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.